The shares of Array BioPharma Inc. have increased by more than 19.69% this year alone. The shares recently went down by -2.73% or -$0.43 and now trades at $15.32. The shares of Banco Santander (Mexico), S.A., Institucion de Banca Multiple, Grupo Financiero Santander (NYSE:BSMX), has slumped by -11.22% year to date as of 05/21/2018. The shares currently trade at $6.49 and have been able to report a change of -6.75% over the past one week.
The stock of Array BioPharma Inc. and Banco Santander (Mexico), S.A., Institucion de Banca Multiple, Grupo Financiero Santander were two of the most active stocks on Monday. Investors seem to be very interested in what happens to the stocks of these two companies but do investors favor one over the other? We will analyze the growth, profitability, risk, valuation, and insider trends of both companies and see which one investors prefer.Next 5Y EPS Growth: 10.00% versus 1.40%
When a company is able to grow consistently in terms of earnings at a high compound rate have the highest likelihood of creating value for its shareholders over time. Analysts have predicted that ARRY will grow it’s earning at a 10.00% annual rate in the next 5 years. This is in contrast to BSMX which will have a positive growth at a 1.40% annual rate. This means that the higher growth rate of ARRY implies a greater potential for capital appreciation over the years.Profitability and Returns
Growth alone cannot be used to see if the company will be valuable. Shareholders will be the losers if a company invest in ventures that aren’t profitable enough to support upbeat growth. In order for us to accurately measure profitability and return, we will be using the EBITDA margin and Return on Investment (ROI), which balances the difference in capital structure. These figures suggest that BSMX ventures generate a higher ROI than that of ARRY.Cash Flow
The value of a stock is ultimately determined by the amount of cash flow that the investors have available. Over the last 12 months, ARRY’s free cash flow per share is a negative -0.01.Valuation
ARRY currently trades at a P/B of 12.06, and a P/S of 18.75 while BSMX trades at a forward P/E of 8.32, a P/B of 16.43, This means that looking at the earnings, book values and sales basis, ARRY is the cheaper one. It is very obvious that earnings are the most important factors to investors, thus analysts are most likely to place their bet on the P/E.Analyst Price Targets and Opinions
The mistake some people make is that they think a cheap stock has more value to it. In order to know the value of a stock, there is need to compare its current price to its likely trading price in the future. The price of ARRY is currently at a -28.34% to its one-year price target of 21.38. Looking at its rival pricing, BSMX is at a -29.3% relative to its price target of 9.18.
When looking at the investment recommendation on say a scale of 1 to 5 (1 being a strong buy, 3 a hold, and 5 a sell), ARRY is given a 1.60 while 2.80 placed for BSMX. This means that analysts are more bullish on the outlook for BSMX stocks.Insider Activity and Investor Sentiment
Short interest or otherwise called the percentage of a stock’s tradable shares currently being shorted is another data that investors use to get a handle on sentiment. The short ratio for ARRY is 5.07 while that of BSMX is just 2.51. This means that analysts are more bullish on the forecast for BSMX stock.
The stock of Array BioPharma Inc. defeats that of Banco Santander (Mexico), S.A., Institucion de Banca Multiple, Grupo Financiero Santander when the two are compared, with ARRY taking 5 out of the total factors that were been considered. ARRY happens to be more profitable, generates a higher ROI, has higher cash flow per share, higher liquidity and has a lower financial risk. When looking at the stock valuation, ARRY is the cheaper one on an earnings, book value and sales basis. Finally, the sentiment signal for ARRY is better on when it is viewed on short interest.